Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

Share Price is delayed by 15 minutes
Get Live Data
112.50    2.50 (2.27%)
Bid:
111.00
Ask:
114.00
Spread: 3.00 (2.703%)
Market Cap: £15.17m
ITX Live PriceLast checked at - London Stock Exchange

Intraday Itaconix Plc Share Chart

Director/PDMR Shareholding

5 May 2015 07:01

RNS Number : 0960M
Revolymer PLC
05 May 2015
 

5 May 2015

 

Revolymer plc ("Revolymer" or "the Group")

Awards under Long Term Incentive Plan and other share awards

 

Revolymer (AIM: REVO) announces the grant of awards under the Revolymer plc Long Term Incentive Plan ("LTIP") and other share awards to its executive directors Kevin Matthews and Robin Cridland.

 

The LTIP was adopted by the board of directors of Revolymer plc (the "Board") on 29 June 2012 and its remuneration committee has approved the following grants on 30 April 2015:

· To the CEO Kevin Matthews a nil cost option over 567,568 ordinary shares

· To the CFO Robin Cridland a nil cost option over 349,550 ordinary shares.

 

The vesting period of these grants is three years and they only become exercisable if challenging performance conditions are met; namely that 50% of the grant becomes exercisable if the weighted average ordinary share price in the 180 day period ending on the third anniversary of grant is £0.75. Between weighted average ordinary share prices of £0.75 and £1.00, vesting shall be pro-rata and on a straight line basis between 50% and 100%. Below £0.75 the grants are not exercisable and lapse in full.

 

The Board also requires the executive directors to maintain minimum interests (of at least 420,000 ordinary shares for Kevin Matthews and 388,000 ordinary shares for Robin Cridland) before selling any ordinary shares that are the result of exercise, except that they may sell that number of ordinary shares that are required to satisfy any income tax and employee's national insurance liabilities arising at exercise. This requirement shall not apply on a change of control, or other transaction with substantially the same effect.

 

Also on 30 April 2015, the Board authorised the issue to Robin Cridland of 36,036 fully paid up ordinary shares in Revolymer plc ("New Shares") in recognition of his fulfilment of the role of Acting CEO during 2014 before the arrival of Kevin Matthews. Following the issue of the New Shares, Mr Cridland will hold 52,836 ordinary shares representing approximately 0.1% per cent. of the Company's issued share capital.

 

Application has been made to the London Stock Exchange for the 36,036 New Shares to be admitted to trading on AIM ("Admission"). Admission is expected to occur at 8:00 am on 8 May 2015. Following Admission, the total number of ordinary shares in the Company will be 56,597,176 with each Ordinary Share carrying the right to one vote. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in ACR under the FSA's Disclosure and Transparency Rules.

 

Ends

 

For further information please contact:

Revolymer plc

+44 (0) 1244 283 500

Kevin Matthews / Rob Cridland

 

 

Panmure Gordon (UK) Limited

+44 (0) 20 7886 2500

Hugh Morgan / Adam James (Corporate Finance)

Charles Leigh-Pemberton (Corporate Broking)

 

 

About Revolymer

Revolymer is an AIM quoted company (registered number 08024489) that designs, develops and formulates novel polymers to improve the performance of its customers' and partners' products.

The vision for Revolymer is to build a high growth, high quality margin, specialty materials business based on proprietary polymer technology that provides responsive or smart multi-functional materials. The Board believes that the Company's technology has broad application. Revolymer aims to generate growing high quality revenue streams by either licensing its proprietary technologies or through the supply of proprietary products using an outsourced manufacturing model. Current target markets are Household Products, Personal Care and Nicotine Gum.

www.revolymer.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSEANSFEEXSEFF
Date   Source Headline
23rd Jun 20205:31 pmRNSLaunch of Fundraise
19th May 20207:00 amRNSNew Loan Funding
5th May 20209:05 amRNSSecond Price Monitoring Extn
5th May 20209:00 amRNSPrice Monitoring Extension
5th May 20207:00 amRNSStrong Revenue Momentum and Extended Funding
17th Mar 20207:00 amRNSCompany Update on Funding and Business Plan
4th Mar 20207:00 amRNSNew Collaboration in Biodegradable Packaging
25th Feb 20207:00 amRNSOrder for Sustainable Detergent Ingredient
20th Feb 20207:00 amRNSHolding(s) in Company
20th Feb 20207:00 amRNSHolding(s) in Company
18th Feb 20202:49 pmRNSHolding(s) in Company
18th Feb 20209:31 amRNSBlock listing Interim Review
12th Feb 20207:15 amRNSNew Supply and License Agreements with New Wave
10th Feb 20207:00 amRNSNew BIO*AsterixT Product Line
28th Jan 20207:00 amRNSIntroduction of New Detergent Polymer
21st Jan 20202:14 pmRNSHolding(s) in Company
17th Jan 20207:00 amRNSTermination of Chelates Agreement
9th Jan 20207:00 amRNSFull Year Trading Update
8th Jan 20207:00 amRNSNew patent issued for detergent compositions
7th Jan 20207:00 amRNSFirst order to Croda for new odour control polymer
18th Dec 20198:00 amRNSCommencement of Trading on US OTCQB Market
24th Oct 20197:00 amRNSExpansion of Croda Supply & Joint Marketing Agrmt
23rd Oct 20197:00 amRNSIntroduction of New Odour Control Product Line
21st Oct 20195:57 pmRNSHolding(s) in Company
18th Oct 20197:00 amRNSTrading Update
27th Sep 20197:00 amRNSRecognition from Biofuels Digest
16th Sep 20195:11 pmRNSHolding(s) in Company
10th Sep 20197:00 amRNSInterim results
30th Aug 20193:17 pmRNSHolding(s) in Company
30th Aug 20197:00 amRNSAppointment of New Chief Financial Officer
22nd Aug 201911:05 amRNSSecond Price Monitoring Extn
22nd Aug 201911:00 amRNSPrice Monitoring Extension
20th Aug 20197:00 amRNSHolding(s) in Company
16th Aug 20199:00 amRNSPrice Monitoring Extension
6th Aug 20194:50 pmRNSHolding(s) in Company
5th Aug 20197:00 amRNSPDMR Shareholding
2nd Aug 20192:05 pmRNSSecond Price Monitoring Extn
2nd Aug 20192:00 pmRNSPrice Monitoring Extension
2nd Aug 201911:05 amRNSSecond Price Monitoring Extn
2nd Aug 201911:00 amRNSPrice Monitoring Extension
29th Jul 20196:03 pmRNSBlock listing Interim Review
19th Jul 20193:28 pmRNSResult of AGM
17th Jul 20197:00 amRNSHalf-Year Trading Update
10th Jul 20194:41 pmRNSSecond Price Monitoring Extn
10th Jul 20194:35 pmRNSPrice Monitoring Extension
9th Jul 20195:19 pmRNSHolding(s) in Company
27th Jun 20197:00 amRNSPreliminary Results
14th Jun 20197:00 amRNSNotice of Results
29th May 20197:00 amRNSSale of Minority Interest in Alkalon
21st May 20197:00 amRNSFirst personal care purchase order from Nouryon

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.